CytomX Therapeutics, Inc. (CTMX) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped CTMX stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: CytomX Therapeutics, focusing on innovative oncology treatments, currently represents a high-risk, high-reward investment. Its strong analyst consensus, promising pipeline reports, and strategic partnerships present considerable upside potential, particularly in the mid-to-long-term horizons. However, the competitive and regulatory nature of its field introduces risks that should not be overlooked. CytomX could outperform broader market averages if it navigates these challenges successfully. The saved 1-year distribution is P10 $3.5, P50 $7, and P90 $11.5.
Last analyzed · Model: gpt-4o
CytomX Therapeutics, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $3.5 | Pessimistic plausible scenario |
| P50 | $7 | Median scenario |
| P90 | $11.5 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
CytomX Therapeutics has strong analyst support, recent positive clinical results, and strategic partnerships. These indicate significant potential upside, albeit investors should remain cautious due to the competitive oncology sector.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this CTMX analysis generated?
March 22, 2026.
Is this a guaranteed CTMX prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full CTMX stock analysis · CTMX sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.